Clinical Trial Detail

NCT ID NCT04240002
Title A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Filgrastim + Fludarabine + Gilteritinib

Age Groups: child adult

Additional content available in CKB BOOST